Effects of Pectin Supplementation in Diarrhea-predominant Irritable Bowel Syndrome
NCT ID: NCT02270268
Last Updated: 2016-03-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
114 participants
INTERVENTIONAL
2011-11-30
2013-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Pectin on Flora Intestinal Colonization and Maintenance After Fecal Transplantation
NCT02016469
The Effects of Laxative-probiotic Sequential Treatment in the Irritable Bowel Syndrome Patients
NCT02254629
Efficacy of a Probiotic Blend to Reduce Gastrointestinal Symptoms in Patients With Irritable Bowel Syndrome
NCT05819281
Multi Strain Probiotic Preparation in Patients With Irritable Bowel Syndrome
NCT04662957
Fibre and Gas in Irritable Bowel Syndrome
NCT03265002
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
pectin
a kind of soluble dietary fiber
Pectin
Pectin （Andeli Ltd. Yantai, China）, 24g/d for six weeks
Placebo
maltodextrin
maltodextrin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pectin
Pectin （Andeli Ltd. Yantai, China）, 24g/d for six weeks
maltodextrin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Admitted for diarrhea-predominant irritable bowel syndrome
Exclusion Criteria
* Cancer
* Inflammatory bowel disease
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nanjing PLA General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gao Tao
Nanjing PLA General Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tao Gao, M.D.
Role: PRINCIPAL_INVESTIGATOR
Nanjing PLA General Hospital
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011NLY073
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.